JP7792252B2 - 新規組換えジアミンオキシダーゼおよび過剰ヒスタミンによって特徴づけられる疾患の治療のためのその使用 - Google Patents

新規組換えジアミンオキシダーゼおよび過剰ヒスタミンによって特徴づけられる疾患の治療のためのその使用

Info

Publication number
JP7792252B2
JP7792252B2 JP2021548232A JP2021548232A JP7792252B2 JP 7792252 B2 JP7792252 B2 JP 7792252B2 JP 2021548232 A JP2021548232 A JP 2021548232A JP 2021548232 A JP2021548232 A JP 2021548232A JP 7792252 B2 JP7792252 B2 JP 7792252B2
Authority
JP
Japan
Prior art keywords
dao
recombinant
amino acid
wild
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021548232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520862A5 (enExample
JP2022520862A (ja
Inventor
ベーム，トーマス
ジルマ，ベルント
ボルト，ニコル
グルドバクツ，エリーザベト
Original Assignee
メディツィニシェ ウニベルジテート ウィーン
ウニヴェルズィテート・フューア・ボーデンクルトゥーア・ウィーン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディツィニシェ ウニベルジテート ウィーン, ウニヴェルズィテート・フューア・ボーデンクルトゥーア・ウィーン filed Critical メディツィニシェ ウニベルジテート ウィーン
Publication of JP2022520862A publication Critical patent/JP2022520862A/ja
Publication of JP2022520862A5 publication Critical patent/JP2022520862A5/ja
Application granted granted Critical
Publication of JP7792252B2 publication Critical patent/JP7792252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03022—Diamine oxidase (1.4.3.22)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Library & Information Science (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
JP2021548232A 2019-02-19 2020-02-18 新規組換えジアミンオキシダーゼおよび過剰ヒスタミンによって特徴づけられる疾患の治療のためのその使用 Active JP7792252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19157932.5 2019-02-19
EP19157932 2019-02-19
PCT/EP2020/054197 WO2020169577A1 (en) 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Publications (3)

Publication Number Publication Date
JP2022520862A JP2022520862A (ja) 2022-04-01
JP2022520862A5 JP2022520862A5 (enExample) 2023-02-27
JP7792252B2 true JP7792252B2 (ja) 2025-12-25

Family

ID=65493995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548232A Active JP7792252B2 (ja) 2019-02-19 2020-02-18 新規組換えジアミンオキシダーゼおよび過剰ヒスタミンによって特徴づけられる疾患の治療のためのその使用

Country Status (14)

Country Link
US (1) US20220145269A1 (enExample)
EP (1) EP3927817B1 (enExample)
JP (1) JP7792252B2 (enExample)
KR (1) KR20210132650A (enExample)
CN (1) CN113785052B (enExample)
AU (1) AU2020225319B2 (enExample)
BR (1) BR112021015865A2 (enExample)
CA (1) CA3130751A1 (enExample)
EA (1) EA202192305A1 (enExample)
ES (1) ES3041133T3 (enExample)
IL (1) IL285452B2 (enExample)
MX (1) MX2021010050A (enExample)
SG (1) SG11202107659SA (enExample)
WO (1) WO2020169577A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
WO2022072718A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
EP4496488A4 (en) * 2022-03-21 2025-11-26 Cedars Sinai Medical Center METHODS AND COMPOSITIONS FOR THE SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE INTESTINAL MICROBIOME
IL317379A (en) * 2022-06-03 2025-02-01 Oyster Point Pharma Inc AAV vector encoding diamine oxidase and its uses
EP4782002A1 (en) * 2025-01-27 2026-07-29 DR Healthcare S.L.U. Diamine oxidase (dao) for use in the treatment of infertility
CN121975758B (zh) * 2026-04-02 2026-07-14 华中科技大学同济医学院附属同济医院 组胺氧化酶蛋白及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510044A (ja) 1997-07-17 2001-07-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改変された、背側組織に影響する因子および組成物
JP2008505869A (ja) 2004-07-07 2008-02-28 アルベルト・ミスビヒラー ジアミノオキシダーゼ含有医薬組成物
JP2014518632A (ja) 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
JP2017532045A (ja) 2014-10-14 2017-11-02 ハロザイム インコーポレイテッド アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
IT1317067B1 (it) * 2000-11-29 2003-05-26 Univ Roma Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico.
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2536016C (en) * 2002-08-16 2017-01-10 Paul L. Deangelis Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CA2660286A1 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2012028891A1 (en) * 2010-09-02 2012-03-08 Debreceni Egyetem Perorally applicable preparation containing histaminase of vegetable origin, resistant to pepsin and trypsin and a process for producing it
WO2023122254A2 (en) * 2021-12-22 2023-06-29 The Board Of Trustees Of The Leland Stanford Junior University Methods to elicit desire to mate and mating behavior

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510044A (ja) 1997-07-17 2001-07-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改変された、背側組織に影響する因子および組成物
JP2008505869A (ja) 2004-07-07 2008-02-28 アルベルト・ミスビヒラー ジアミノオキシダーゼ含有医薬組成物
JP2014518632A (ja) 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
JP2017532045A (ja) 2014-10-14 2017-11-02 ハロザイム インコーポレイテッド アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biochemistry，2009年，vol. 48, no. 41，pp. 9810-9822
J Biol Chem, 2018, vol. 293, no. 3, pp. 1070-1087
J Biol Chem，1994年，vol. 269, no. 13，pp. 9921-9925
J Biol Inorg Chem，2002年02月13日，vol. 7, no. 6，pp. 565-579

Also Published As

Publication number Publication date
ES3041133T3 (en) 2025-11-07
EP3927817C0 (en) 2025-08-20
AU2020225319B2 (en) 2025-05-29
KR20210132650A (ko) 2021-11-04
US20220145269A1 (en) 2022-05-12
BR112021015865A2 (pt) 2021-10-05
SG11202107659SA (en) 2021-09-29
WO2020169577A1 (en) 2020-08-27
CA3130751A1 (en) 2020-08-27
EP3927817B1 (en) 2025-08-20
CN113785052A (zh) 2021-12-10
IL285452B2 (en) 2025-07-01
CN113785052B (zh) 2024-06-28
IL285452A (en) 2021-09-30
MX2021010050A (es) 2021-09-21
JP2022520862A (ja) 2022-04-01
EP3927817A1 (en) 2021-12-29
AU2020225319A1 (en) 2021-10-14
IL285452B1 (en) 2025-03-01
EA202192305A1 (ru) 2021-12-08

Similar Documents

Publication Publication Date Title
EP3927817B1 (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
US20190192630A1 (en) Mutated fibroblast growth factor (fgf) 1 and methods of use
US20200040051A1 (en) Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
US20160237133A1 (en) Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
US20180057554A1 (en) Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose
WO2016048995A2 (en) Fgf19 truncations and mutants and uses thereof
US20190151416A1 (en) Fibroblast growth factor (fgf) 1 proteins with glucose lowering ability and reduced mitogenicity
US20170291931A1 (en) Fgf2 truncations and mutants and uses thereof
US20190276510A1 (en) Use of fibroblast growth factor 1 (fgf1)-vagus nerve targeting chimeric proteins to treat hyperglycemia
US20180319857A1 (en) Fgf2 truncations and mutants and uses thereof
US20230097335A1 (en) Fibroblast growth factor 1 (fgf1) mutant proteins that selectively activate fgfr1b to reduce blood glucose
HK40064258A (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
HK40064258B (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
WO2014014819A2 (en) Methods of treating glucose metabolism disorders
WO2014014816A2 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251215

R150 Certificate of patent or registration of utility model

Ref document number: 7792252

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150